Impaired fibrinolysis in patients with thrombotic or haemostatic defects.
In a retrospective study of the 47 patients examined for thrombotic defects, 34 had prolonged euglobulin lysis times (ELT) with 27 of these also having elevated tissue-plasminogen activator inhibitor (t-PAI) activity. Twenty three of the 57 patients examined for possible bleeding problems had prolonged ELT with 15 of this group also having raised levels of t-PAI. There was a statistically greater (P less than 0.005) incidence of elevated t-PAI in the thrombotic group. The incidence of 40% patients with prolonged ELT in the haemostasis group was surprising and perhaps represents some compensatory mechanism to combat bleeding. Thus in vitro tests showed that a reduced capacity for fibrinolysis was present in diametrically opposed groups.
Sloan
I G
IG
Department of Medicine, Monash Medical School, Alfred Hospital, Prahran, Australia.
Firkin
B G
BG
D000293:Adolescent; D000328:Adult; D000368:Aged; D001778:Blood Coagulation Disorders / Q000503:physiopathology*; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D002648:Child; D002675:Child, Preschool; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000032:analysis*; D010972:Platelet Activating Factor / Q000031:analogs & derivatives*; D010979:Platelet Function Tests; D012189:Retrospective Studies; D013927:Thrombosis / Q000503:physiopathology*
D001779:Blood Coagulation Factors; D015849:Plasminogen Inactivators; D010972:Platelet Activating Factor; D005340:Fibrinogen